ClinicalTrials.gg
Drug

Amivantamab clinical trials

Also written JNJ-61186372 and RYBREVANT.

Includes 1 study of Amivantamab and Recombinant Human Hyaluronidase.

studies test it
31
open now
15
in phase 3
6
first study started
2016

How each study uses amivantamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the amivantamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 May 2021 · RYBREVANT · BLA 761210 (FDA, Drugs@FDA)
European Union
9 Dec 2021 · Rybrevant · EMEA/H/C/005454 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Amivantamab
23
Amivantamab IV
2
Amivantamab Intravenous
2

Brand

RYBREVANT
3

Development codes

JNJ-61186372
19
CNTO-4424
1
JNJ-611
1
JNJ-372
1

Other names

Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372
1

Studies by the year they started

31 studies that test it; most in 2024 (9)

Studies that test amivantamab, by start year
YearStudies
20161
20181
20191
20201
20213
20225
20233
20249
20253
20264

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
21
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 15

Janssen Research & Development, LLC (14) · Yonsei University (3) · University of Colorado, Denver (1) · M.D. Anderson Cancer Center (1) · AstraZeneca (1) · Institute of Cancer Research, United Kingdom (1) · Trisha Wise-Draper (1) · Memorial Sloan Kettering Cancer Center (1)

Often tested with

Tested in the same studies.

Lazertinib (3) · Capmatinib (1) · Tepotinib (1) · Osimertinib (1) · Docetaxel (1) · Mutant-selective EGFR Inhibitor JIN-A02 (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Amivantamab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 12

Studies that test amivantamab.

Studies

Open first, then newest update. How each study uses amivantamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 31

See all 31 studies that test amivantamab →

Given beside what is tested · 14 — amivantamab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with amivantamab

Codes

What other systems call amivantamab · ClinicalTrials.gg INT001661

  • MeSH (NLM) C000718215amivantamabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 0JSR7Z0NB6AMIVANTAMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2549199One source FDA
  • Wikidata Q106957199amivantamabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C124993AmivantamabOne source FDA
  • DrugBank DB16695One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.